Literature DB >> 16099733

Markers for perioperative myocardial ischemia: what both interventional cardiologists and cardiac surgeons need to know.

Johannes Mair1, Angelika Hammerer-Lercher.   

Abstract

All novel markers of myocardial ischemia (ischemia-modified albumin, choline, unbound free fatty acids) lack cardiac specificity. Therefore, for the specific detection of myocardial ischemia selective blood sampling from an inserted coronary sinus catheter is needed, which limits the applicability of these markers in most clinical routine settings. In addition, the superiority of these novel markers over the calculation of myocardial lactate production, the current criterion standard for the laboratory diagnosis of myocardial ischemia, has not been demonstrated so far, and even comparative data is frequently lacking. Further the superiority of these new candidate markers over lactate determination for the diagnosis of myocardial ischemia in peripherally drawn blood samples has not been demonstrated either, and these novel parameters appear not to be a breakthrough for laboratory diagnosis of myocardial ischemia during or after percutaneous coronary interventions or coronary artery bypass grafting. The determination of cardiac troponin I or troponin T is the current criterion standard for the laboratory diagnosis of myocardial damage due to their higher sensitivities and specificities compared to creatine kinase isoenzyme MB. According to current knowledge, troponin increases in peripherally drawn blood samples must be regarded as an indicator of myocardial necrosis which, however, may be limited, only detectable by troponin and may be missed by creatine kinase isoenzyme MB determination. After on-pump coronary artery bypass grafting the generally applied troponin discriminator limits are not valid as there is limited, inevitable cardiac tissue damage occurring during the surgical procedure. Therefore, troponins are significantly increased after reperfusion of the arrested heart over values seen before bypass and also in patients without complications. Perioperative myocardial infarctions can be reliably identified by their characteristic troponin time courses, and both peak concentrations and time of peak values are diagnostic criteria. Troponin release is lower in off-pump compared to on-pump bypass surgery. Despite the controversy over the significance of troponin elevations after clinically uncomplicated and successful procedures, it is tempting to postulate that less myocardial damage as detected by troponin release is beneficial for the patient. After elective percutaneous coronary interventions, only troponin increases >8-fold the upper reference limit were associated with increased mortality in long-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16099733     DOI: 10.1532/HSF98.20051123

Source DB:  PubMed          Journal:  Heart Surg Forum        ISSN: 1098-3511            Impact factor:   0.676


  4 in total

Review 1.  [Biomarkers in cardiology--state of the art 2007].

Authors:  Johannes Mair
Journal:  Wien Med Wochenschr       Date:  2007-02

2.  N-acetylcysteine use among patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized trials.

Authors:  José Eduardo G Pereira; Regina El Dib; Leandro G Braz; Janaina Escudero; Jason Hayes; Bradley C Johnston
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

3.  Evaluation of Melatonin Therapy in Patients with Myocardial Ischemia-Reperfusion Injury: A Systematic Review and Meta-Analysis.

Authors:  Tingting Lv; Junwei Yan; Yunwei Lou; Zeying Zhang; Mengfei Ye; Jiedong Zhou; Fangyi Luo; Chenchen Bi; Hui Lin; Jian Zhang; Hangyuan Guo; Zheng Liu
Journal:  Oxid Med Cell Longev       Date:  2022-03-03       Impact factor: 6.543

4.  Effect of Melatonin on Cardiac Injury after Primary Percutaneous Coronary Intervention: a Randomized Controlled Trial.

Authors:  Padideh Ghaeli; Shaghayegh Vejdani; Atefeh Ariamanesh; Azita Hajhossein Talasaz
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.